There is a global crisis of antibiotic resistance in part because of the collateral damage of antibiotic use. Reduction in antibiotic consumption is clearly important to minimize this problem. Limiting treatment duration may be the most clinically palatable means of reducing antibiotic consumption. Antimicrobial stewardship programs play an important role in this process. Their effectiveness may be increased by drawing on evidence from randomized controlled trials regarding optimal antibiotic duration. However, in most clinical scenarios, the recommended duration of therapy in published guidelines is based on expert opinion. Biological markers, such as procalcitonin, have been shown to reduce antimicrobial consumption with no adverse outcome in 11 randomized controlled trials. Although procalcitonin may not be the perfect biomarker, the concept of procalcitonin-guided antibiotic discontinuation after clinical stabilization, in conjunction with antimicrobial stewardship programs, appears to be ready for introduction into clinical practice.
Infection control plays an important role in preventing spread of antibiotic-resistant bacteria. However, there are a number of potential options by which antibiotic administration can be modified to reduce antibiotic resistance. In the hospital setting, these include frontend restriction of antibiotic use, whereby prescribers need prior approval to use certain agents [1] . Antibiotic cycling and use of combination antibiotic therapy have been suggested as other options to reduce resistance, although evidence supporting their use is lacking [1] . At the 45th Annual Meeting of the Infectious Diseases Society of America, Louis Rice delivered the Maxwell Finland Lecture on modalities to reduce antimicrobial resistance; he concluded that reduction in length of antibiotic courses was the antibiotic use strategy most likely to be effective in reducing antibiotic resistance [2] .
The proposed mechanism was that shorter courses of antibiotics reduce selective pressure on bacterial flora and, therefore, prevent emergence of resistance [2] .
The importance of antibiotic stewardship programs as a modality to improve quality of prescribing and to reduce duration of antibiotic use has been emphasized in a number of recent reviews and guidelines [3] . Without external pressures, prescribers may not willingly curtail antibiotic duration or de-escalate their empirical antibiotic choices. Studies from Europe and the United States have shown that de-escalation was only performed in 11%-55% of patients in whom it would have been appropriate [4] [5] [6] [7] .
Use of an antibiotic discontinuation policy is a key potential role of antibiotic stewardship programs. The feasibility of use of basic clinical, laboratory, and radiologic measures as a means of curtailing antibiotic duration was established by Singh et al [8] ; in their trial, use of the clinical pulmonary infection score to objectively assess the presence of ventilator-associated pneumonia (VAP) after 3 days of empirical antibiotic therapy was associated with much shorter antibiotic therapy, compared with the standard care group (3 days vs 9.8 days). In addition, there was a lower frequency of development of antimicrobial resistance, with no difference in mortality and length of intensive care unit (ICU) stay. However, this study was not performed in the context of an antibiotic stewardship program and the standard duration of therapy for VAP in this study was 10-21 days, which is much longer than the current standard of 7 days.
In a more recent evaluation of antimicrobial stewardship in an ICU by Micek et al [9] , antibiotic therapy initiated for clinically suspected VAP was discontinued if a noninfective etiology for infiltrate was identified or signs and symptoms suggested active infection had resolved. In this study, the duration of antibiotics in the antibiotic discontinuation group was 2 days shorter than that in the conventional treatment group (mean 6 standard deviation, 6.0 6 4.9 days vs 8.0 6 5.6 days), with no difference in occurrence of a secondary episode of VAP, hospital mortality, and ICU length of stay.
These studies of simple antibiotic discontinuation policies demonstrate that antibiotic stewardship should be able to reduce antibiotic use safely, even in critically ill patients. The purpose of this article is to review 2 additional strategies to encourage shorter durations of antibiotic use: (1) application of results of randomized trials of differing antibiotic durations to clinical practice and (2) use of biomarkers in conjunction with clinical signs of resolution of infection, to drive discontinuation of antibiotics.
Application of Results of Randomized Trials of Differing Antibiotic Durations to Clinical Practice
There are, unfortunately, few randomized controlled trials on comparative effectiveness of antibiotic regimens of differing durations (Table 1) . This may not be surprising, given the cost and complexity of organizing randomized trials.
Community-Acquired Pneumonia (CAP)
Current guidelines of the Infectious Diseases Society of America (IDSA) recommend that patients with CAP should be treated for a minimum of 5 days [3] . At least 5 randomized controlled trials (RCTs) have shown that antibiotic treatment for 5 days is as effective and safe as longer treatment courses [11-13, 15, 17] . Two meta-analyses have also shown the efficacy and safety of shorter course (#7 days) antimicrobial treatment in CAP [27, 28] . Although trials in these meta-analyses have emphasized short-course studies with azithromycin (which has a long intracellular half-life) and have not exclusively enrolled hospitalized patients, a recent RCT has even demonstrated that intravenous amoxicillin for 3 days as treatment for CAP was as successful as 8 days of antibiotic treatment [16] .
The weight of current evidence would suggest that CAP can be treated for 5 days, perhaps even for as few as 3 days. The presence of bacteremic Staphylococcus aureus pneumonia, empyema, lung abscess, necrotizing pneumonia, or some specific agents of infection (for example, Legionella) may mandate longer durations.
Ventilator-Associated Pneumonia (VAP)
Traditionally, VAP was treated for 14-21 days. However, current IDSA guidelines generally recommend 7 days treatment for VAP, if a causative organism is other than a nonfermentative gram-negative bacillus (GNB), such as Pseudomonas aeruginosa or Acinetobacter species [29] . This is based on a multicenter RCT by Chastre et al [18] that demonstrated that patients who received appropriate initial empirical therapy of VAP for 8 days had outcomes similar to those of patients who received therapy for 15 days. Recommendations for a longer course of treatment for VAP due to nonfermentative GNB is based on a subgroup analysis in the study, which showed a greater rate of recurrence and/or relapse for those with a nonfermentative GNB who were given 8 days of therapy. In contrast, a recent retrospective analysis could not find a higher recurrence rate in patients with VAP caused by nonfermentative GNB who received #8 days of antibiotic therapy, compared with $ 9 days [30] .
Bacterial Meningitis
The duration of antibiotics for bacterial meningitis is based on tradition and expert opinion rather than on RCTs. The recommended duration of antimicrobial therapy in IDSA guidelines is 7-21 days, depending on the organism (Table 2 ) [31] . However, shorter courses have been studied in some settings. One or 2 intramuscular injections of long-acting chloramphenicol (oily suspension) has been recommended by the World Health Organization for epidemic meningococcal meningitis since 1995. Nathan et al [36] demonstrated the noninferiority of a single intramuscular administration of ceftriaxone to single intramuscular administration of oily chloramphenicol in an RCT with 510 patients with suspected meningococcal meningitis in Niger. The treatment failure rates for the intention-to-treat analysis, although evaluated at 72 hours, were only 9% in both arms. Although this result is not necessarily applicable to the management of meningococcal meningitis in developed countries, a retrospective analysis and a prospective case series in New Zealand showed that 3 days treatment with benzyl penicillin for meningococcal meningitis was very successful [37] [38] [39] .
Pyelonephritis
The IDSA guidelines for management of pyelonephritis published in 1999 recommended 14 days of treatment for most situations [35] . This recommendation is based on an RCT conducted by Stamm et al [21] that demonstrated that 2 weeks of ampicillin or trimethoprim-sulfamethoxazole (TMP-SMX) had no difference in clinical cure rate, compared with 6 weeks of ampicillin or TMP-SMX. Subsequently, a meta-analysis of (14-42 days) antibiotic therapy in acute pyelonephritis in adults [40] . No statistically significant differences were found between the short-and long-course treatment of acute pyelonephritis in terms of clinical success, bacteriologic efficacy, relapse, and adverse events.
In the past 10 years, several RCTs evaluating short courses (#7 days) of fluoroquinolones have been conducted [23] [24] [25] [26] . Talan et al [24] demonstrated that 7 days of treatment with ciprofloxacin more successfully treated pyelonephritis than did 14 days of treatment with TMP/SMX. Two other RCTs showed that 5 days of treatment with levofloxacin (750 mg once daily) was as efficacious as 10 days of treatment with ciprofloxacin (500 mg twice daily) [25, 26] .
Infective Endocarditis (IE)
Recommended antimicrobial treatment durations for IE are variable (2 weeks to $8 weeks) and depend on the causative organism, minimum inhibitory concentrations of antibiotics against the causative organism, and whether native or prosthetic valves are involved (Table 2) . A 2-week treatment course is limited to only 2 situations [33] . The first is treatment of uncomplicated native valve endocarditis caused by highly penicillin-susceptible viridians group streptococci and Streptococcus bovis with penicillin G or ceftriaxone plus gentamicin. This is based on an RCT by Sexton et al [19] that demonstrated that ceftriaxone plus gentamicin for 2 weeks was equivalent to ceftriaxone for 4 weeks and some case series that showed high cure rates (94%-100%) for short-duration regimens [41] [42] [43] . The second situation is the treatment of uncomplicated native valve right-sided endocarditis caused by oxacillin-susceptible S. aureus with nafcillin or oxacillin plus gentamicin. This regimen is supported by several clinical trials including RCTs, none of which were planned to compare treatment durations [44] [45] [46] [47] [48] .
Historically, short-course (#20 days) treatments for IE were associated with higher relapse rates. Although these studies had a number of methodological flaws, the overall contribution of prolonged antibiotic duration for endocarditis to development of resistance seems limited. However, further study of shortened durations of intravenously administered antibiotic courses for IE may be warranted for the economic and social gains that may be achieved.
Complicated Intra-abdominal Infections
Current IDSA guidelines recommend use of antibiotics in the treatment of complicated intra-abdominal infections for 4-7 days unless it is difficult to achieve adequate source control [34] . A retrospective analysis of 929 patients with intra-abdominal infection that was performed by Hendrick et al [30] showed that an antibiotic treatment duration #7 days was associated with the same mortality rate and a lower recurrence rate than longer antibiotic courses. On the basis of this result, a multicenter RCT has commenced to evaluate short-course (3-5 days) antimicrobial treatment for intra-abdominal infections, compared with antimicrobial treatment for up to 2 days after normalization of white blood cell count, temperature, and gastrointestinal function (NCT00657566).
Skin and Soft-Tissue Infection
A randomized study has compared 5 with 10 days of antibiotics in patients with uncomplicated cellulitis [49] . However, only a minority of these patients were hospitalized [49] . We are not aware of studies evaluating different treatment durations for complicated skin and soft-tissue infection, although there is a trend toward shorter durations in RCTs evaluating new antibiotics for this indication.
Catheter-Related Bloodstream Infection
For uncomplicated catheter-related bloodstream infection, recommended durations of antibiotic therapy by IDSA guidelines are shown in Table 2 . There are no randomized trials of differing durations of therapy for catheter-related bloodstream infection, with recommendations being based on retrospective case series and expert opinion.
Conditions in Which No Randomized Trials Have Been Performed
The duration of antibiotic therapy for conditions, such as bloodstream infection, aspiration pneumonia, septic arthritis, and osteomyelitis, in hospitalized patients have not yet been assessed in randomized trials. Although recommendations of treatment duration for other conditions are sometimes indicated for certain defined organisms, there is a lack of literature regarding treatment duration for culture-negative infections.
Conclusions
A number of studies have been recently undertaken that have compared shorter durations of antibiotics than have been typically been used in the past. The extent to which knowledge of the efficacy of shortened durations of antibiotics for common infections has been translated into changes in clinical practice is almost completely unknown. Deviation of patient characteristics from those included in RCTs is likely to be common in clinical practice and may encourage physicians to use more prolonged antibiotic courses. Furthermore, uncertainty regarding the meaning of subgroup analyses (eg, relapse rates of nonfermentative GNBs in VAP) may further hamper extension of RCT results in clinical practice. Regardless, controlled investigation of shorter antibiotic treatment durations should be encouraged by the National Institutes of Health. On the basis of published RCTs, shorter treatment durations seem just as likely as more prolonged, traditional regimens to cure most common bacterial infections.
Use of Biomarkers
Biomarkers, such as C-reactive protein (CRP) or procalcitonin, have been increasingly studied as an aid to the clinical decision to commence or discontinue antibiotics. Although biomarkers have been used to aid the decision to commence antibiotic therapy, our discussion emphasizes those studies examining use of procalcitonin in making the decision to discontinue antibiotic therapy.
Serum procalcitonin levels increase dramatically within 2-4 hours after onset of systemic inflammation, persist as long as the inflammatory process continues, and normalize with recovery [50] . The biological half-life of procalcitonin is 22-26 hours [51] . Procalcitonin levels are increased in moderate-to-severe bacterial infections but remain at comparatively low levels in viral infections and nonspecific inflammatory diseases [52] .
In the past decade, a large number of observational studies on procalcitonin as a serum marker of bacterial infections have been conducted [53] [54] [55] [56] . Subsequently, procalcitonin has been investigated for the purpose of limiting antibiotic use in RCTs in 2 major patient categories: patients with respiratory tract infection in the community and critically ill patients in the ICU. Eleven RCTs on procalcitonin-guided antimicrobial treatment have been published thus far, and all have shown significant reduction of antimicrobial consumption in those whose treatment is guided by procalcitonin, compared with those treated conventionally (Table 3) .
Christ-Crain et al [57] first demonstrated that procalcitoninguided antimicrobial initiation was an effective strategy to limit antibiotic use in patients with lower respiratory tract infection. In 3 subsequent RCTs by these investigators, a similar advantage of procalcitonin-guided antimicrobial initiation and/or discontinuation was observed in hospitalized patients with CAP [58] , acute respiratory tract infection in a primary care setting [60] , and acute exacerbation of chronic obstructive pulmonary disease [59] . Indeed, in the RCT studying CAP, patients with procalcitonin-guided antimicrobial initiation and discontinuation received 7 days fewer antibiotics, compared with those treated conventionally [57] . The safety of procalcitonin-guided antibiotic initiation and discontinuation in patients with lower respiratory tract infection (CAP 68.1%, exacerbation of COPD 16.8%, and acute bronchitis 11.1%) in emergency departments of tertiary care hospitals was demonstrated as a primary outcome in a multicenter RCT (ProHOSP trial). In this large study, the mean duration of antibiotics in the procalcitonin group was 3 days shorter than that in those managed conventionally (5.7 days vs 8.7 days) [66] .
In critically ill patients, if clinicians have a suspicion of bacterial infectious diseases, it is unrealistic to expect that antibiotics will be withheld, regardless of the level of procalcitonin. Therefore, an alternative approach-procalcitonin-guided antibiotic discontinuation after clinical stabilization-has been evaluated in 5 RCTs in critically ill patients [59, [61] [62] [63] 67] . Although definitions in these studies have varied, each has shown a reduction in antibiotic duration.
Nobre et al [61] conducted an RCT in patients in a medical ICU and showed a 4-day reduction in the duration of antimicrobial treatment in the group whose antibiotic duration was guided by the procalcitonin results, compared with the conventionally treated group. The median duration of antibiotic therapy was 6 days in those whose antibiotic discontinuation was guided by the procalcitonin results, compared with 10 days in the conventionally treated group. In addition, a 2-day shorter stay in the ICU was observed in the procalcitonin group in this study. There was no difference in mortality or recurrence of primary infection between the 2 groups. A significant reduction of the duration of antimicrobial treatment in critically ill patients with no adverse clinical outcome has also been demonstrated in 2 RCTs in surgical ICUs by a German group [62, 63] . Stolz et al [65] demonstrated that procalcitonin-guided antibiotic discontinuation in patients with VAP increased the number of ''antibiotic-free days alive'' 28 days after VAP onset (13 days vs 9.5 days); this translated to a reduction in the overall duration of antibiotic therapy of 27% in the procalcitonin group. Again, there was no adverse impact on length of hospital stay or mortality rate. The safety of procalcitonin-guided antibiotic initiation and discontinuation in critically ill patients was also demonstrated in a 621-patient study, in which 28-and 60-day mortality was not affected [67] . In this study, patients in the procalcitonin group had significantly more days without antibiotics at 28 days after enrollment than patients in the control group (14.3 days vs 11.6 days).
Conclusions
Although the results of RCTs examining procalcitonin as a guide to cessation of antibiotics in the hospital setting appear to be very promising, there are a number of concerns that need to be raised. First, the intensity of antibiotic stewardship programs at institutions where those studies were conducted is unclear. It is possible that unnecessary antibiotic use could have been reduced by antibiotic stewardship activities without monitoring procalcitonin. Second, there seems to be a considerable geographical publication bias, with all published studies being performed in Europe. Indeed, 5 of 6 RCTs in the management of respiratory tract infection were conducted by the same Swiss group. Third, the use of procalcitonin in the management of a number of infection types has never been studied. Fourth, cutoff values of procalcitonin levels to discourage or encourage antibiotic use are variable among studies even in the same patient category. Fifth, daily measurement of procalcitonin level, which is done in some RCTs, seems to be wasteful and potentially expensive. The cost-effectiveness of a procalcitonin-guided strategy needs to be fully evaluated. Finally, although antibiotic use has been reduced, a corresponding reduction in isolation of antibiotic-resistant organisms has not yet been demonstrated.
SUMMARY
Each of the strategies for reducing duration of antibiotic courses that we have evaluated carries potential problems. Even antibiotic stewardship, which we believe should be the cornerstone of interventions to reduce antibiotic use, requires considerable human resources and a significant budget for implementation (especially if computer-assisted resources are used). The culture of an institution may be a major determinant of the success of an antibiotic stewardship program and this may be difficult to alter quickly. Application of results of RCTs into practice is clearly necessary, but availability of funding to perform clinically relevant studies is limited.
The global issue of antimicrobial resistance has already placed us in a critical situation in which antibiotic consumption needs to be aggressively reduced beyond our current levels. An integration of biomarker-guided antibiotic duration into antibiotic stewardship programs appears to be essential. The concept of procalcitonin-guided antibiotic discontinuation after clinical stabilization is more likely to be clinically acceptable than is reliance on procalcitonin measurement alone. The evidence is mounting that we need to more aggressively intervene in reducing duration of antibiotic therapy in our hospitals.
